Flumazenil as a diagnostic tool in the differential diagnosis of coma in a critically ill patient
Flumazenil, a specific benzodiazepine antagonist, has a high affinity for and competitively binds to the benzodiazepine-GABA (gamma aminobutyric acid) receptor complex. 1,2 Gamma aminobutyric acid is a major inhibitory CNS transmitter, therefore stimulation of this receptor complex by a benzodiazepine agonist results in decreased neural excitability. Flumazenil is capable of reversing or blocking the CNS effects of benzodiazepines. It has been used for antagonism of general anaesthesia induced or maintained with benzodiazepines 3-s for the reversal of benzodiazepine sedation, in short, diagnostic and therapeutic procedures, 6 for the diagnosis and/or management of deliberate or accidental overdosages, 7-u and has improved neurological function in patients with Grade III-IV hepatic encephalopathy. 12-IS We report a case of a patient with suspected septic encephalopathy whose level of consciousness improved markedly following flumazenil administration; subsequent blood analysis revealed diazepam and active metabolites two weeks following discontinuation of benzodiazepine administration.
Case report
A 77-yr-old man was admitted for elective revision of a fight knee prosthesis. Immediately before surgery, the patient developed peritonitis with septic shock requiring resuscitation and ventilatory support in the ICU. He underwent emergency laparotomy for drainage of a ruptured peridiverticular abscess and resection of the sigmoid colon and a portion of the small bowel. Postoperatively, cardiac studies indicated the patient had sustained a perioperative myocardial infarction and mechanical ventilation was required for 22 days during the gradual recovery from his septic process. Two days after his discharge from the ICU (post-op day 25), the patient required readmission to the ICU with obtundation and septic shock secondary to a urinary tract infection. At that time, in- During a three-week period, the patient became confused and less cooperative until gradually he became obtunded and unresponsive. A standard 16 channel EEG taken on day 42 showed burst suppression and a theta coma pattern consistent with a severe encephalopathy. A lumbar puncture was performed which revealed unremarkable CSE During the course of his ICU admission, the patient had received numerous doses of narcotic analgesics and sedatives which included diazepam (1-2 mg q15 rain,/v) lorazepam (1 mg q15 min, iv), midazolam (2-5 mg,/v), and haldol (2.5-5 mg, ira) on a prn basis. All benzodiazepines were discontinued on day 51. During the five days prior to discontinuing benzodiazepines, the patient had received total doses of midazolam -16 mg, diazepam -12.5 mg and lorazepam -7 mg. Repeat EEG showed no improvement and since a burst suppression pattern is also consistent with benzodiazepine intoxication, a qualitative benzodiazepine screen of blood and urine was performed on day 64. On day 65, a single /v injection of flumazenil (Anexate R Hoffman-Laroche, 2 mg) was given over one minute during continuous EEG recording. Initially, the EEG revealed generalized delta and burst suppression consistent with coma from a diffuse encephalopathy. Within 30 see of the injection of flumazenil the patient's eyes opened wide, he became alert and nodded appropriately to questions. The EEG tracing showed that the injection of flumazenil induced immediate electro-encephalographic arousal which persisted for approximately five hours (Figure) . The patient gradually became more obtunded and eventually returned to his pre-flumazenil state (unresponsive to painful stimuli). On day 86, the patient died of multiorgan failure secondary to sepsis. Although two weeks had passed since this patient had received benzodiazepines, both serum and urine were positive for benzodiazepines. In the serum, diazepam and its metabofite nordiazepam were detected, with nordiazepam predominating, indicating a minimum concentration of 1. only oxazepam, a metabolite of diazepam, was detected, indicating a minimum concentration of 150 nmol. L -~ (42 ng. ml-i). The therapeutic serum levels of diazepam and oxazepam are reported as 100-500 ng. ml -I and 300-400 ng. ml-~ respectively, and therapeutic blood levels vary considerably from patient to patient. 16-18
Discussion
It is not uncommon for the febrile septic patient to develop an altered mental state. Septic encephalopathy, a term used to refer to the syndrome of altered brain function, is related to the presence of microorganisms or their toxins in the blood. =9 Many factors may act alone or in combination and result in brain dysfunction. These include CNS infections, direct endotoxin effects, reduced cerebral perfusion, metabolic derangements, liver insufficiency and multi-system organ failure. 20 These patients present with a wide range of symptoms including agitation, disorientation, obtundation, stupor and in the patient with severe encephalopathy, as demonstrated in our case, coma. The theta coma and burst suppression pattern on EEG was suggestive of anoxic, septic or metabolic encephalopathy including severe drug intoxication. It was therefore necessary to determine the aetiology of this patient's responsive state. Although the EEG findings are often non-specific in this patient population, the EEG is important to rule out status epilepticus as a cause of coma since it may not be associated with grand mal seizures. In light of the positive plasma and urine benzodiazepine levels it was decided to use the benzodiazepine antagonist flumazenil to determine if benzodiazepine intoxication was contributing to his neurological dysfunction.
The immediate and dramatic clinical response that was seen after flumazenil suggested that the largest factor contributing to this patient's comatose state was the presence of benzodiazepines. The sudden arousal from deep coma to normal wakefulness demonstrated by the EEG confirmed the clinical impression. Since flumazenil has no direct effect on the EEG, 21 the arousal response could only be attributed to antagonism of benzodiazepine receptors. However, apart from an indirect effect of the patient's hepatic disease decreasing benzodiazepine metabolism, it was possible that the patient's depressed level of consciousness was due to his underlying hepatic failure since benzodiazepine-like agonists have been proposed to be synthesized by the liver in hepatic failure. For example, previous reports showing improvement in neurological function following flumazenil administration, occurred in patients who presented with acute deterioration of hepatic function. 22-24 Similar results have also been shown in animal models of fulminant hepatic failure. 25 However, our patient demonstrated only mild increases in hepatic enzymes and the prothrombin time, a maker of hepatic function, was normal. As well, clinical improvement in neurological function with flumazenil has occurred only in patients with significant hepatic dysfunction, who present with Grade Ill-IV hepatic coma. The clinical improvement seen in patients with grade I-II hepatic encephalopathy is less impressive and often not evident. 12-15 We feel, therefore, that the cause of our patient's comatose state was primarily benzodiazepine intoxication, as opposed to his underlying mild hepatic disease.
Benzodiazepines were detected in the patient's serum and urine two weeks after any of these agents had been given. Both diazepam and its metabolite nordiazepam were present in the blood and oxazepam, a metabolite of diazepam, was present in the urine. Unfortunately, only a qualitative assay was available. It is important to note that the detection process for oxazepam in the urine initially requires hydrolysis of the glucuronide bond with oxazepam thereby allowing oxazepam to be extracted. Since this hydrolysis process does not occur during blood analysis, oxazepam would not be detected in the serum.
Since benzodiazepines depend on hepatic metabolism and renal excretion for their clearance, disturbance of hepatic and renal function, coupled with ongoing administration of diazepam and lorazepam would lead to accumulation of benzodiazepines within the fat stores of the body. This could then serve as a potential reservoir for the release of drug, even two weeks after the last dose had been given. The effect of flumazenil is quite rapid and the duration of action is short. Since flumazenil has no effect on the bioavailability, plasma concentrations or half-life of the benzodiazepine agonists, 2,26 its actions are solely the result of its binding interaction with the benzodiazepine receptor. For instance, the half-life of flumazenil is between 0.7 and 1.3 hr while the half-life of diazepam can be as long as 50 hr, is with active metabolites eliciting longer half-lives. For example, the formation of nordiazepam from diazepam can extend biological half-life threefold, is Therefore, the re-emergence of the sedative effects of benzodiazepines and their active metabolites may occur once the effects of flumazenil have dissipated, as demonstrated in this case. If the patient were stable and ready for tracheal extubation, a continuous infusion of flumazenil to maintain an appropriate level of consciousness would have been considered.
In conclusion, this case report describes the use of flumazenil as a diagnostic tool in a septic patient whose comatose state was due to an unrecognized benzodiazepine intoxication. The EEG provided an objective measure of the patient's response to flumazenil. Flumazenil administration is useful as a diagnostic aid in critically ill patients with a depressed level of consciousness and may identify benzodiazepine intoxication in a patient whose metabolism and clearance of benzodiazepines is impaired.
